LIPO Lipella Pharmaceuticals Full Business Value

The price history of Lipella Pharmaceuticals (LIPO) reflects the enterprise value dynamics, which currently stand at . The company's financial foundation relies on patent protection for methods of combating severe inflammation, ensuring stability until the start of active sales. The brand's high authority in urological therapy is supported by a qualified staff of scientists conducting specialized research in optimal conditions.

LIPO (lipella.com) Total Company Value history from 07/04/2022 to 10/28/2026

Lipella Pharmaceuticals (LIPO) - metric breakdowns and financial figures

- price and consensus price forecast:

Market Chart Lipella Pharmaceuticals Inc|LIPO - Price Target Chart

- market capitalization data:

Market Valuation Lipella Pharmaceuticals|LIPO - Total Company Value

- book capitalization data:

Net Asset Value per Share Lipella Pharmaceuticals|LIPO - Company Book Value|Market Capitalization to Net Assets lipella.com|LIPO - Company Total Assets

- debt and liquidity data:

Comprehensive company analysis:Lipella Pharmaceuticals Inc (LIPO)

Original product of Lipella Pharmaceuticals

Enterprise value represents the market valuation of a business, combining market capitalization with net debt to determine the actual price for a full buyout of the company. By analyzing the total enterprise value, an investor can compare the costs of acquiring assets of Lipella Pharmaceuticals (LIPO) with the efficiency of implementing robotic molecule screening and the automation of data processing for clinical trials of urological drugs.

Competitor analysis for Lipella Pharmaceuticals

Haleon PLC - Company Buyout Price|Total Company Value Kenvue Corp|VRNA: Full Business Value|Total Company Value MENS|LGND (ligand.com) - Total Enterprise Value|Total Company Value Amneal AMRX|Full Business Value Perrigo Company PLC|Alvotech Corp (ALVO) - Enterprise Value|Value Adjusted for Debt and Cash Liquidia Inc. (LQDA)|Enterprise Value GLPG (Galapagos NV)|anipharmaceuticals.com - Enterprise Value|Total Company Value MannKind (MNKD)|AMPH: Value Adjusted for Debt and Cash|PCRX (Pacira) - Total Company Value|ARS Corp (SPRY) - Real Price to Acquire Entire Company|TBPH (Theravance Biopharma) - Enterprise Value|Enterprise Value aquestive.com (AQST)|scPharmaceuticals Inc. (SCPH) - Real Price to Acquire Entire Company|Value Adjusted for Debt and Cash TECX (tectonictx.com)|TNXP: Total Company Value|SXTC - Total Enterprise Value|Real Price to Acquire Entire Company Eupraxia Pharma EPRX|BHST - Aggregate Business Value|Enterprise Value eXoZymes EXOZ|Oramed Pharmaceuticals Inc. (ORMP) - Value Adjusted for Debt and Cash|Enterprise Value ENTX (Entera Bio Ltd)|Total Enterprise Value HYFT|ABVC BioPharma (ABVC) - Total Company Value|Value Adjusted for Debt and Cash CPIX (cumberlandpharma.com)|Total Company Value Quantum BioPharma QNTM|Total Company Value FibroGen Inc FGEN|Enterprise Value TELO (Telomir Pharma)|RANI: Company Buyout Price|Total Company Value synergychc.com (SNYR)|Rallybio (RLYB) - Full Business Value|Enterprise Value LEXX (Lexaria Bioscience Corp)|Total Enterprise Value PULM|Total Company Value Pheton Holdings Ltd (PTHL)|Total Company Value APM (aptorumgroup.com)|Total Company Value Lyra Therapeutics, Inc. LYRA|Total Company Value Impact BioMedical, Inc. IBO|TNF Pharma - Enterprise Value|cbdMD, Inc. (YCBD) - Enterprise Value|Real Price to Acquire Entire Company PainReform Limited PRFX|CYTO (Altamira Therapeutics Ltd.) - Value Adjusted for Debt and Cash|Total Company Value OptiNose, Inc. OPTN|Full Business Value pieris.com|Procaps (PROC) - Enterprise Value|Value Adjusted for Debt and Cash Petros Pharmaceuticals Inc (PTPI)|Enterprise Value QLI (Qilian International Holding Group Limited)|ACELYRIN Inc. - Enterprise Value|Total Company Value TFF Pharmaceuticals (TFFP)